Celcuity LLC (CELC)

Celcuity LLC (CELC) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $3.2B; returns 1 day -0.5%, 1 week +15.3%, 1 year -7.5%.

Celcuity LLC is a clinical-stage biotechnology company focused on developing targeted therapies for oncology. Their lead candidate, gedatolisib, is a potent inhibitor of the PAM (PI3K/AKT/mTOR) pathway, which is implicated in various cancers. Celcuity's business model revolves around burning cash on R&D to create future value, primarily through the potential commercialization of gedatolisib.

Groups CELC belongs to

• Biotechnology
• Clinical Stage Biotech
• Oncology
• Clinical Stage
• Cancer Therapeutics
• Breast Cancer Treatment
• Healthcare
• Precision Medicine
• Pharmaceuticals

CELC financial model: income statement, cash flow and balance sheet